Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Pyxis Oncology (PYXS) to $7 from $5 and keeps a Buy rating on the shares after the company provided a clinical data update on studies evaluating Micvo as a therapy for relapsed/metastatic head and neck squamous cell carcinoma. The firm says the “consistent” efficacy and “manageable” safety profile increase its confidence in the second-line setting.